News

Zacks.com on MSN1h
Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?
Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking ...
Tirzepatide reduces food intake and appetite, and affects brain functioning, more than placebo and liraglutide
Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...
MetaVia Inc.: MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum ...
Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass., July 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology ...
tastylive1h
Why I'm Bullish on Eli Lilly as the Next Evolution in Weight Loss Unfolds
The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...
Gastroenterology Advisor5h
GLP-1RAs Linked to Higher Risk for GERD, Cholelithiasis
GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.